Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Abstract Text:

    janie parrinoJanie Parrino,lewis h mccurdyLewis H McCurdy,brenda d larkinBrenda D Larkin,ingelise j gordonIngelise J Gordon,steven e ruckerSteven E Rucker,mary e enamaMary E Enama,richard a koupRichard A Koup,mario roedererMario Roederer,robert t bailerRobert T Bailer,zoe moodieZoe Moodie,lin guLin Gu,lihan yanLihan Yan,barney s grahamBarney S Graham, ,

    Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.

    Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Publishing Authors By Initials

    j parrinoJ Parrino,lh mccurdyLH McCurdy,bd larkinBD Larkin,ij gordonIJ Gordon,se ruckerSE Rucker,me enamaME Enama,ra koupRA Koup,m roedererM Roederer,rt bailerRT Bailer,z moodieZ Moodie,l guL Gu,l yanL Yan,bs grahamBS Graham, ,

    For similar viruses: dna viruses: poxviridae: chordopoxvirinae: orthopoxvirus: vaccinia virus research abstracts see: viruses: dna viruses: poxviridae: chordopoxvirinae: orthopoxvirus: vaccinia virus research

    PUBMED ID PMID:

    MEDLINE DATE:

    Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Journal Published:

    PUBLICATION TYPE: Research Support, N.I.H., Intr

    Journal: Vaccine

    VOLUME: 25

    Page Numbers: 1513-25

    Journal Abbreviation: Vaccine

    ISSN: 0264-410X

    DAY: 7

    MONTH: 11

    YEAR: 2006

    Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8406899

    Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Keywords Mesh Terms:

    KEYWORDS: Vaccinia virus

    MESH TERMS: immunology

    Chemical & Substance for Abstract: Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Information

    Substance Name: Smallpox Vaccine

    Registry Number: 0

    Grant and Affiliation Information for Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

    AFFILIATION: Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

    Country: Netherlands

    Netherlands Research PublicationNetherlands Research Publication

    AGENCY: United States NIAID

    GRANT: Z01 AI005062-03

    ACRONYM: AI

    MEDLINETA: Vaccine

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Safety, immunogenicity and efficacy of modified vaccinia Ankara MVA against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News